Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hormonal diseases focused Diurnal said it achieved positive headline results from proof-of-concept clinical trial for its oral testosterone formulation.
This study evaluated the pharmacokinetics, safety and tolerability of formulation in a target patient group of 24 adult men with primary or secondary hypogonadism.
It was shown to achieve testosterone levels within the healthy young male adult normal range after oral administration, with levels that were less variable than testosterone undecanoate.
The safety and tolerability of two different doses found were no serious adverse events in the study, and levels of the potent testosterone derived androgen, dihydrotestosterone, were lower than with testosterone undecanoate.
At 1:35pm: (LON:DNL) Diurnal Group Plc share price was +1.5p at 32p